ORAMED PHARMACEUTICALS INC. (ORMP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-700K 0 700K 1.4M 2.1M Q1 '16: 125K Q1 '16: 125K Q2 '16: -163K Q3 '16: 929K Q4 '16: 610K Q1 '17: 611K Q2 '17: 617K Q3 '17: 618K Q4 '17: 611K Q1 '18: 604K Q2 '18: 617K Q3 '18: 617K Q4 '18: 674K Q1 '19: 666K Q2 '19: 682K Q3 '19: 681K Q4 '19: 674K Q1 '20: 674K Q2 '20: 681K Q3 '20: 681K Q4 '20: 674K Q1 '21: 665K Q1 '21: 666K Q2 '21: 681K Q2 '21: 674K Q3 '21: 683K Q3 '21: 682K Q4 '21: 674K Q1 '22: 666K Q2 '22: 674K Q3 '22: 682K Q4 '22: 681K Q1 '23: 666K Q2 '23: 674K Q3 '23: 0 Q4 '23: 0 Q1 '25: 2M Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q2 '21 Q2 '22 Q3 '23 Q4 '25

Gross Profit Quarterly

0 5K 10K 15K Q1 '25: 13K Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating Income Quarterly

-12M -8M -4M 0 4M 8M 12M Q2 '17: -2.2M Q3 '17: -2.9M Q4 '17: -2.7M Q1 '18: -3.1M Q2 '18: -4.5M Q3 '18: -3.1M Q4 '18: -4.6M Q1 '19: -3.6M Q2 '19: -4.1M Q3 '19: -2.3M Q4 '19: -2.4M Q1 '20: -4M Q2 '20: -2.3M Q3 '20: -3M Q4 '20: -5.8M Q1 '21: -4.9M Q1 '21: -6.6M Q2 '21: -6.1M Q2 '21: -4.5M Q3 '21: -7.4M Q3 '21: -7.5M Q4 '21: -8.1M Q1 '22: -11.3M Q2 '22: -11.4M Q3 '22: -8.2M Q4 '22: -9.7M Q1 '23: -5.2M Q2 '23: -3.8M Q3 '23: -2.9M Q4 '23: -3.9M Q1 '24: -3M Q2 '24: -3.1M Q3 '24: -3.1M Q4 '24: -3.6M Q1 '25: -4.5M Q2 '25: -2.5M Q3 '25: -2.4M Q4 '25: -5.7M Q1 '26: -3.7M Q2 '26: -2.8M Q2 '18 Q3 '19 Q4 '20 Q3 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-30M 0 30M 60M 90M Q1 '17: -3.2M Q2 '17: -2M Q3 '17: -2.7M Q4 '17: -2.5M Q1 '18: -2.9M Q2 '18: -4.4M Q3 '18: -2.9M Q4 '18: -4.3M Q1 '19: 3.7M Q2 '19: 4.1M Q3 '19: -26.4M Q4 '19: -2.5M Q1 '20: -3.7M Q2 '20: -2.3M Q3 '20: -3M Q4 '20: -5.6M Q1 '21: -4.6M Q1 '21: -6.1M Q2 '21: -5.2M Q2 '21: -3.9M Q3 '21: -7.6M Q3 '21: -7.5M Q4 '21: -8.1M Q1 '22: -10.7M Q2 '22: -10.5M Q3 '22: -7.1M Q4 '22: -8.5M Q1 '23: -3.4M Q2 '23: -1.2M Q3 '23: -3.2M Q1 '24: 1.5M Q2 '24: 9.2M Q3 '24: -19.6M Q4 '24: -10.2M Q1 '25: -7.6M Q2 '25: 13.3M Q3 '25: 48.4M Q4 '25: 10M Q1 '26: 38.3M Q2 '26: 78.2M Q1 '18 Q2 '19 Q3 '20 Q2 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

-700K 0 700K 1.4M 2.1M Q1 '16: 4K Q2 '16: -8K Q3 '16: 502K Q4 '16: 187K Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q2 '18: -86K Q3 '18: 0 Q4 '18: 35K Q1 '19: 55K Q2 '19: 0 Q3 '19: 0 Q1 '25: 2M Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q2 '16 Q1 '17 Q2 '18 Q1 '19 Q1 '25 Q4 '25

Operating Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q1 '17: -2.9M Q2 '17: -2.4M Q3 '17: -2M Q4 '17: -2.7M Q1 '18: -3.5M Q2 '18: -3.8M Q3 '18: -4.6M Q4 '18: -4.1M Q1 '19: -1.9M Q2 '19: -3.7M Q3 '19: -3.3M Q4 '19: -3M Q1 '20: -3.6M Q2 '20: -3.4M Q3 '20: -2.5M Q4 '20: -6.2M Q1 '21: -3.7M Q2 '21: -5.6M Q2 '21: -4.7M Q3 '21: -6.1M Q3 '21: -5.5M Q4 '21: -6.9M Q1 '22: -9.1M Q2 '22: -8.5M Q3 '22: -2.2M Q4 '22: -8.1M Q1 '23: -5.5M Q2 '23: -2.6M Q3 '23: -694K Q4 '23: -1.4M Q1 '24: -1.5M Q2 '24: 2.1M Q3 '24: -7.1M Q4 '24: -1.9M Q1 '25: -3.5M Q2 '25: -3.5M Q3 '25: -1.6M Q4 '25: -466K Q1 '26: -2.9M Q2 '26: -200K Q1 '18 Q2 '19 Q3 '20 Q3 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q4 '15: -2.2M Q1 '16: 2.3M Q2 '16: -2.2M Q3 '16: 6.8M Q2 '17: -2.4M Q3 '17: -2M Q2 '18: -3.8M Q3 '18: -4.7M Q4 '18: -4.1M Q1 '19: -1.9M Q2 '19: -3.7M Q3 '19: -3.3M Q4 '19: -3M Q1 '20: -3.6M Q2 '20: -3.4M Q3 '20: -2.5M Q4 '20: -6.5M Q1 '21: -3.7M Q2 '21: -5.6M Q2 '21: -4.7M Q3 '21: -6.2M Q3 '21: -5.6M Q1 '22: -9.2M Q2 '22: -8.5M Q3 '22: -2.4M Q4 '22: -8.4M Q1 '23: -5.7M Q2 '23: -2.7M Q3 '23: -726K Q4 '23: -1.4M Q1 '24: -1.5M Q2 '24: 2.1M Q3 '24: -7.1M Q4 '24: -1.9M Q1 '25: -3.5M Q2 '25: -3.5M Q3 '25: -1.6M Q4 '25: -468K Q1 '26: -2.9M Q2 '26: -202K Q2 '17 Q1 '19 Q2 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '21: 28M Q2 '21: 30.7M Q3 '21: 34.5M Q1 '22: 38.7M Q2 '22: 38.8M Q3 '22: 39.1M Q1 '23: 40M Q2 '23: 40.2M Q3 '23: 40.4M Q1 '24: 41.6M Q2 '24: 41.6M Q3 '24: 40.9M Q1 '25: 41.2M Q2 '25: 42.6M Q3 '25: 42.8M Q1 '26: 42M Q2 '26: 42.5M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '13: 0.24 Q4 '13: 0.24 Q1 '14: 0.53 Q2 '14: 0.54 Q3 '14: 0.61 Q4 '14: 0.66 Q1 '15: 0.69 Q2 '15: 0.66 Q3 '15: 0.68 Q4 '15: 0.70 Q1 '16: 0.69 Q4 '16: 0.86 Q1 '17: 0.96 Q2 '17: 0.96 Q3 '17: 0.79 Q4 '17: 0.77 Q1 '18: 0.73 Q2 '18: 0.88 Q3 '18: 0.86 Q4 '18: 0.93 Q1 '19: 0.94 Q2 '19: 0.87 Q3 '19: 0.82 Q4 '19: 0.72 Q1 '20: 0.72 Q2 '20: 0.59 Q3 '20: 0.58 Q4 '20: 0.66 Q1 '21: 0.62 Q4 '22: -0.94 Q1 '23: -1.29 Q2 '23: -1.59 Q3 '23: -1.85 Q4 '24: -0.48 Q1 '25: -0.71 Q2 '25: -0.62 Q3 '25: 0.99 Q4 '25: 1.49 Q1 '26: 2.59 Q2 '26: 4.12 Q3 '14 Q4 '15 Q3 '17 Q4 '18 Q1 '20 Q4 '22 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.